Skip to content
DataLookout
Menu

NCT07722611

A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).

StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 5 → 8 locations
  2. Minor Trial sites expanded: 1 → 5 locations
    • Start date changed from estimate of Oct 21, 2026 to Oct 29, 2026
  3. Minor Study sites: 1 to 2
  4. Minor Start date pushed from Oct 7, 2026 to Oct 21, 2026
    • Study title revised
  5. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Study sites: 0 to 1
    • Start date: Sep 21, 2026 to Oct 7, 2026
    • Secondary endpoints: details revised at 11 of 12 entries
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Clinicohematologic Response (CHR) Rate
Timeframe: Up to approximately Week 52

Secondary (12)

Clinicohematologic Response Sustained for a 24-Week Time Period (CHR24)
Number of Participants Who Experience an Adverse Event (AE)
Number of Participants Who Discontinue Study Treatment Due to an AE
Duration of Clinicohematologic Response Sustained for a 24-Week Time Period (DOCHR24)
Duration of Clinicohematologic Response (DOCHR)
Show 7 moreShow less
Duration of Hematologic Remission (DOHR)
Number of Participants Who Experience Phlebotomies
Disease Progression Rate
Number of Participants Who Experience Thrombotic Events
Number of Participants Who Experience Major Hemorrhagic Events
Change From Baseline in Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4) Total Symptom Score
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7a Total Fatigue Score

Arms and interventions

BomedemstatExperimental

Participants will receive bomedemstat daily for up to approximately 52 weeks. Per protocol, dosage may be adjusted within specified time parameters for each participant to achieve and maintain protocol-specified platelet and hematocrit target ranges. Eligible participants who do not discontinue study treatment at Week 52, may continue to receive study treatment.

Best Available Therapy (BAT)Active comparator

Participants will receive either ropeinterferon alfa-2b or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to approximately 52 weeks.

Drugs: Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b

Sites

8 sites in 3 countries

United States 4, Israel 3, Canada 1